Prenatal editing halts progression of Hurler syndrome in pre-clinical model
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
List view / Grid view
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
Chemical synthesis of guide RNAs for CRISPR-Cas9 gene editing enables accurate and rapid production of CRISPR libraries and screening in an arrayed, one-gene-per-well fashion.
Researchers have created an algorithm that can predict the efficiencies of guide RNAs for CRISPR, potentially making it more precise.
A CRISPR gene editing technique has been developed to restore dystrophin, which is missing in many Duchenne muscular dystrophy (DMD) patients.
A CRISPR-Cas9 method has been used to identify which genes play a role in repairing zebrafish spinal cord injuries.
Scientists have said that researchers need to be more aware of unintended mutations to human embryos following CRISPR-Cas9 genome editing.
Researchers have used CRISPR to create a new technology that can switch off almost any gene in cells, called CRISPRoff.
In this application note, discover how pools of synthetic crRNAs can produce a phenotype as strong as, or stronger, than any one of the component crRNAs in arrayed CRISPR screening experiments.
Researchers have shown that prime editing is able to effectively edit genes in mice but without the off-target effects of CRISPR.
Researchers have reported that nano-micelles can be used to efficiently deliver CRISPR-Cas9 to edit genes in the brains of mice.
A new CRISPR gene therapy for chronic pain has been shown in mice to temporarily repress a gene involved in sensing pain.
Researchers have used nanobodies to act as an assistant to CRISPR, bringing in effectors to turn specific genes on and off.
Researchers have shown that a guide RNA can be used in CRISPR gene editing to ensure sequential Cas9 cuts to DNA.
CRISPR-Cas9 and stem cell technologies have been used to create a cellular model of acute myeloid leukaemia, revealing therapeutic targets.
TALEN was shown to be almost five times more efficient than CRISPR-Cas9 at locating and editing genes in heterochromatin.